Login
$LH
$372.46 +$0.00 (0.0%) After hours

$LH SEC Filings

Filed On Filing
16 Nov 2026 144
12 Nov 2026 Form 4: Caveney Brian J, EVP, Pres of BLS, CMO & CSO

Sold 2,000 shares ($744K)

10 Nov 2026 144
05 Nov 2026 Form 4: Vaughn Bryan T, EVP and President, Diagnostics

Sold 306 shares ($108K)

04 Nov 2026 144
04 Nov 2026 8-K: Regulation FD Disclosure

BURLINGTON, N.C., (Nov. 4, 2026) — Labcorp Holdings, Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that Chief Financial Officer Julia Wang will speak at the UBS Global Healthcare Co...

03 Nov 2026 144
03 Nov 2026 Form 4: Parham Richelle P, Director

Sold 1,078 shares ($389K)

03 Nov 2026 Form 4: Oyegunwa Akinbolade, EVP, CIO & CTO

Received 370 shares by exercise or conversion · Gave up 118 shares to cover exercise price or tax ($42K)

03 Nov 2026 Form 4: Vaughn Bryan T, EVP and President, Diagnostics

Received 500 shares by exercise or conversion · Gave up 194 shares to cover exercise price or tax ($69K)

30 Oct 2026 10-Q
30 Oct 2026 144
28 Oct 2026 8-K: Results of Operations and Financial Condition

BURLINGTON, N.C., October 28, 2026 – Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the third quarter ended September 30, 2026 and updated its full-year ...

21 Oct 2026 8-K: Regulation FD Disclosure

BURLINGTON, N.C., October 21, 2026 - Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of co...

30 Sep 2026 8-K: Regulation FD Disclosure

BURLINGTON, N.C., (Sept. 30, 2026) – Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of 2026 before the market opens on Wedne...

22 Sep 2026 8-K: Regulation FD Disclosure

On September 21, 2026, the Centers for Medicare & Medicaid Services (“CMS”) released preliminary Clinical Laboratory Fee Schedule payment rates applicable from 2027 through 2029 pursuant to the Protecting Access to Medicare Act (“PAMA”)....

10 Sep 2026 8-K: Regulation FD Disclosure

2©2026 Labcorp. All rights reserved. Cautionary Statement Regarding Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements with respect to (i) the estimated 2026 guidan...

03 Sep 2026 Form 4: Oyegunwa Akinbolade, EVP, CIO & CTO

Granted 750 Restricted Stock Unit

03 Sep 2026 Form 4: Meltzer Jonathan C, EVP, COO

Granted 900 Restricted Stock Unit

03 Sep 2026 Form 4: Vaughn Bryan T, EVP and President, Diagnostics

Granted 1,500 Restricted Stock Unit

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support